Lifeworks Advisors LLC Makes New $511,000 Investment in The Clorox Company (NYSE:CLX)

Lifeworks Advisors LLC bought a new position in The Clorox Company (NYSE:CLX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,472 shares of the company's stock, valued at approximately $511,000.

Other hedge funds also recently made changes to their positions in the company. Redwood Park Advisors LLC acquired a new position in shares of Clorox in the 4th quarter valued at $26,000. Wood Tarver Financial Group LLC acquired a new position in shares of Clorox in the 4th quarter valued at $31,000. GKV Capital Management Co. Inc. bought a new stake in shares of Clorox in the 4th quarter worth about $32,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Clorox in the 4th quarter worth about $33,000. Finally, GW&K Investment Management LLC grew its holdings in shares of Clorox by 239.1% in the 1st quarter. GW&K Investment Management LLC now owns 295 shares of the company's stock worth $43,000 after purchasing an additional 208 shares during the last quarter. Institutional investors and hedge funds own 78.53% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on CLX. UBS Group lowered their target price on shares of Clorox from $150.00 to $134.00 and set a "neutral" rating on the stock in a report on Thursday, July 17th. Jefferies Financial Group lowered their target price on shares of Clorox from $167.00 to $145.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Barclays lowered their target price on shares of Clorox from $129.00 to $119.00 and set an "underweight" rating on the stock in a report on Tuesday, July 15th. Wells Fargo & Company decreased their price objective on shares of Clorox from $142.00 to $135.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 9th. Finally, Morgan Stanley decreased their price objective on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $144.83.

Clorox Trading Down 0.5%

Clorox stock traded down $0.62 during trading hours on Friday, reaching $130.80. 1,287,038 shares of the company's stock traded hands, compared to its average volume of 1,776,629. The company has a debt-to-equity ratio of 13.07, a quick ratio of 0.44 and a current ratio of 0.74. The Clorox Company has a fifty-two week low of $117.35 and a fifty-two week high of $171.37. The firm has a market capitalization of $16.12 billion, a price-to-earnings ratio of 23.48, a PEG ratio of 3.46 and a beta of 0.51. The firm's 50 day moving average is $126.77 and its 200-day moving average is $140.29.

Clorox (NYSE:CLX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). The business had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.74 billion. Clorox had a net margin of 9.89% and a return on equity of 324.23%. The business's revenue for the quarter was down 8.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.71 earnings per share. On average, analysts predict that The Clorox Company will post 7.15 earnings per share for the current year.

Insider Buying and Selling at Clorox

In other news, Director Pierre R. Breber purchased 4,000 shares of the business's stock in a transaction that occurred on Wednesday, May 7th. The shares were acquired at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the transaction, the director directly owned 4,000 shares of the company's stock, valued at approximately $546,280. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. 0.57% of the stock is owned by corporate insiders.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.